SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+24.46%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$963M
AUM Growth
+$963M
(+11%)
Cap. Flow
-$20.1M
Cap. Flow
% of AUM
-2.09%
Top 10 Holdings %
Top 10 Hldgs %
42.67%
Holding
134
New
41
Increased
18
Reduced
32
Closed
26
Top Buys
| 1 |
Eli Lilly
LLY
|
$42.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$38.8M |
| 3 |
ONCR
Oncorus, Inc.
ONCR
|
$28.4M |
| 4 |
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
|
$26.1M |
| 5 |
C4 Therapeutics
CCCC
|
$14.6M |
Top Sells
| 1 |
Sanofi
SNY
|
$56.2M |
| 2 |
AbbVie
ABBV
|
$48.2M |
| 3 |
Amgen
AMGN
|
$28M |
| 4 |
Amicus Therapeutics
FOLD
|
$22.6M |
| 5 |
Sarepta Therapeutics
SRPT
|
$16.5M |
Sector Composition
| 1 | Healthcare | 79.61% |
| 2 | Technology | 10.28% |
| 3 | Industrials | 3.68% |
| 4 | Consumer Discretionary | 2.21% |
| 5 | Communication Services | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $69.2M | 6.14% | 410,000 +254,000 | +163% | +$42.9M |
|
2
Merck
MRK
$210B
| $59.6M | 5.29% | 728,808 -155,000 | -18% | -$12.7M |
|
3
Johnson & Johnson
JNJ
$427B
| $53.2M | 4.72% | 338,200 -41,800 | -11% | -$6.58M |
|
4
Novartis
NVS
$245B
| $40.5M | 3.6% | 429,000 +144,000 | +51% | +$13.6M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $38.8M | 3.44% | +625,000 | New | +$38.8M |
|
|
6
AbbVie
ABBV
$372B
| $36.4M | 3.23% | 340,000 -450,000 | -57% | -$48.2M |
|
7
AstraZeneca
AZN
$248B
| $34.5M | 3.06% | 690,473 -129,527 | -16% | -$6.48M |
|
|
ONCR
8
DELISTED
Oncorus, Inc.
ONCR
| $28.4M | 2.52% | +903,111 | New | +$28.4M |
|
|
SGTX
9
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $26.1M | 2.31% | +567,460 | New | +$26.1M |
|
10
Generac Holdings
GNRC
$10.9B
| $24M | 2.13% | 105,663 +38,663 | +58% | +$8.79M |
|
11
Nice
NICE
$8.73B
| $21.1M | 1.87% | 74,481 +12,000 | +19% | +$3.4M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.6M | 1.47% | 745,900 +235,900 | +46% | +$5.25M |
|
13
Kura Oncology
KURA
$686M
| $15.4M | 1.37% | 471,494 +112,000 | +31% | +$3.66M |
|
|
14
C4 Therapeutics
CCCC
$185M
| $14.6M | 1.3% | +443,824 | New | +$14.6M |
|
15
Palo Alto Networks
PANW
$127B
| $13.5M | 1.19% | +37,871 | New | +$13.5M |
|
|
CERE
16
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $13.5M | 1.19% | +811,665 | New | +$13.5M |
|
|
17
Sarepta Therapeutics
SRPT
$1.78B
| $12.8M | 1.13% | 75,000 -96,500 | -56% | -$16.5M |
|
18
AudioCodes
AUDC
$273M
| $11.8M | 1.05% | +428,971 | New | +$11.8M |
|
19
Zymeworks
ZYME
$1.12B
| $11.6M | 1.03% | 245,000 +165,000 | +206% | +$7.8M |
|
20
ALX Oncology
ALXO
$62.7M
| $11.5M | 1.02% | 133,448 -48,622 | -27% | -$4.19M |
|
21
Kornit Digital
KRNT
$669M
| $11.4M | 1.02% | 128,381 -15,000 | -10% | -$1.34M |
|
22
BridgeBio Pharma
BBIO
$9.89B
| $11.2M | 1% | +157,900 | New | +$11.2M |
|
23
Meta Platforms (Facebook)
META
$1.86T
| $10.9M | 0.97% | 39,998 +4,998 | +14% | +$1.37M |
|
24
Microsoft
MSFT
$3.77T
| $10.6M | 0.94% | 47,536 -3,742 | -7% | -$832K |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $10.5M | 0.93% | 597,198 +227,198 | +61% | +$3.98M |
|